Solésence reported second-quarter 2026 revenue of $15.3 million, down from $20.4 million in the prior year period which benefited from a one-time product launch. The company posted a net loss of $158,000 compared to net income of $3.2 million previously, with adjusted EBITDA declining to $523,000 from $3.7 million. Management attributed the decline to lower revenue and non-recurring items in 2025, while noting shipped and on-hand orders totaled $64.9 million for 2026. The filing also disclosed a restatement related to historical inventory costing allocation methodologies identified during the quarter-end review. Solésence operates in the beauty and life science sectors, providing scientifically driven health care solutions and mineral-based sun protection technologies.

Solésence, Inc. through its subsidiary Solésence, LLC, entered into a Settlement Agreement and Release with Refy Beauty Ltd on July 6, 2026, to resolve disputes regarding consumer care products. The company will pay Refy Beauty Ltd the equivalent of $938,000 in twelve equal monthly installments of $78,166.66, with the first installment due August 5, 2026. The agreement also includes a six-month exclusivity period for new SPF product development and potential future supply agreement negotiations. Solésence, Inc. operates in the consumer care and beauty products industry.